Key result
ONCOR registry data reveals a ~36% incidence of CV complications among patients receiving cardio-oncology care.
Why the study?
Limited data are currently available on the outcomes and experiences of specialised cardio-oncology services, and optimal strategies for cardio-oncological care have not been established.
Observational (n=1,142)
Yes
The ONCOR registry is designed to prospectively collect data on cardio-oncological care in the Netherlands to better understand the incidence and impact of cancer therapy-related cardiovascular complications.
Documents substantial CV complications in cardio-oncology patients; leaves open optimal management strategies pending controlled trials.
BACKGROUND: The relative new subspecialty 'cardio-oncology' was established to meet the growing demand for an interdisciplinary approach to the management of cancer therapy-related cardiovascular adverse events. In recent years, specialised cardio-oncology services have been implemented worldwide, which all strive to improve the cardiovascular health of cancer patients. However, limited data are currently available on the outcomes and experiences of these specialised services, and optimal strategies for cardio-oncological care have not been established. AIM: The ONCOR registry has been created for prospective data collection and evaluation of cardio-oncological care in daily practice. METHODS: Dutch hospitals using a standardised cardio-oncology care pathway are included in this national, multicentre, observational cohort study. All patients visiting these cardio-oncology services are eligible for study inclusion. Data collection at baseline consists of the (planned) cancer treatment and the cardiovascular risk profile, which are used to estimate the cardiotoxic risk. Information regarding invasive and noninvasive tests is collected during the time patients receive cardio-oncological care. Outcome data consist of the incidence of cardiovascular complications and major adverse cardiac events, and the impact of these events on the oncological treatment. DISCUSSION: Outcomes of the ONCOR registry may aid in gaining more insight into the incidence of cancer therapy-related cardiovascular complications. The registry facilitates research on mechanisms of cardiovascular complications and on diagnostic, prognostic and therapeutic strategies. In addition, it provides a platform for future (interventional) studies. Centres with cardio-oncology services that are interested in contributing to the ONCOR registry are hereby invited to participate.
No takes yet. Share an insight, caveat, or question.
Kamphuis et al. (2020) conducted an observational in Cancer patients at risk for or with cardiovascular complications (n=1,142). Potentially cardiotoxic cancer therapies was evaluated on Incidence of cardiovascular complications. Initial results from the ONCOR registry of 1,142 cancer patients receiving cardio-oncology care showed 378 cardiovascular complications among 1,038 patients followed for a median of 21.6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: